Livzon Pharmaceutical Group Inc. (FRA:LP6)

Market Cap	2.83B -24.5%
Revenue (ttm)	1.34B -13.7%
Net Income	204.44M -27.3%
EPS	0.23 -26.5%
Shares Out	n/a
PE Ratio	9.47
Forward PE	9.82
Dividend	0.32 (14.22%)
Ex-Dividend Date	Oct 14, 2026

Volume	n/a
Open	2.220
Previous Close	2.200
Day's Range	2.220 - 2.220
52-Week Range	2.080 - 3.580
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 23, 2026

About FRA:LP6

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People’s Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate for the psychiatric and neuro...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 8,878
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LP6

Financial Performance

In 2025, FRA:LP6's revenue was 12.02 billion, an increase of 1.76% compared to the previous year's 11.81 billion. Earnings were 2.02 billion, a decrease of -1.84%.

Financial numbers in CNY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 25, 2026

Data Sources Report a data error